Every major medical-trend survey tells the same story: healthcare costs are rising faster than general inflation, and in international private medical insurance the pressure is acute. When the cost of care climbs year on year and claims outpace premium growth, the loss ratio does the rest of the talking.
The instinct is to reach for the two familiar levers: put premiums up, and squeeze the network for better rates. Both matter. Neither is enough on its own.
Premium increases have a ceiling
Raise premiums too far and you lose the account. Regulators, brokers and corporate buyers are all watching affordability, and in a competitive IPMI market the member simply moves. Premium is a blunt instrument, and it treats the symptom rather than the cause.
Network discounts are the floor, not the ceiling
A negotiated rate lowers the price of a given treatment. It does nothing about whether that treatment was necessary, whether the length of stay was justified, or whether the bill was itemised fairly. Once a book is on good rates, the marginal saving from pushing them further is small. The market has largely accepted that discounts alone are no longer sufficient.
The underused lever is clinical
The larger, more durable savings sit upstream of the invoice, in the question of whether the care was appropriate in the first place. That is a clinical question, and answering it means having clinicians who can engage the treating team on medical necessity, level of care and treatment pathway, not administrators applying a fee schedule after the fact.
Framed properly, this is not about withholding care. It is about the right care, in the right place, at the right time, which is usually both the most clinically defensible option and the most cost-effective one.
Make it defensible
None of this works if it cannot be evidenced. When an insurer or regulator asks why a decision was made, the answer has to be clinical, documented and auditable. That is the standard we hold on every case: the reasoning is recorded as the case progresses, so the loss-ratio benefit and the clinical rationale are one and the same record.
Medical inflation is not going away. The insurers who weather it best will be the ones who pair their network rates with genuine clinical governance over what care happens at all.